Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

SML1394

Sigma-Aldrich

Olmesartan

≥98% (HPLC)

Sinónimos:

4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid, Olmesartan acid

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C24H26N6O3
Número de CAS:
144689-24-7
Peso molecular:
446.50
MDL number:
MFCD09749896
UNSPSC Code:
12352200
PubChem Substance ID:
329825842
NACRES:
NA.77
En este momento no podemos mostrarle ni los precios ni la disponibilidad

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 20 mg/mL, clear

storage temp.

2-8°C

SMILES string

OC(C)(C)C1=C(C(O)=O)N(CC2=CC=C(C3=C(C4=NNN=N4)C=CC=C3)C=C2)C(CCC)=N1

InChI

1S/C24H26N6O3/c1-4-7-19-25-21(24(2,3)33)20(23(31)32)30(19)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)22-26-28-29-27-22/h5-6,8-13,33H,4,7,14H2,1-3H3,(H,31,32)(H,26,27,28,29)

InChI key

VTRAEEWXHOVJFV-UHFFFAOYSA-N

Gene Information

human ... AGTR1(185)

Application

Olmesartan has been used as an angiotensin II receptor 1 (AT1) receptor inhibitor to study the effect of angiotensin II type 1 receptor interactions in the regulation of renal afferent arterioles in angiotensin II-dependent hypertension.[1]

Biochem/physiol Actions

Olmesartan is an Angiotensin II Type I receptor blocker.
Olmesartan is an Angiotensin II Type I receptor blocker. Olmesartan is the active form of the antihypertensive drug olmesartan medoxomil.
Olmesartan possesses anti-inflammatory and anti-oxidative stress properties. It protects neuronal cells against oligomerized amyloid β (Aβ)-induced cellular senescence.[2]

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000390400
0000381193
0000381193
0000390400
0000249586

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Ariadne M Brondi et al.
Journal of analytical methods in chemistry, 2017, 4878316-4878316 (2018-02-03)
A study was carried out to investigate compatibility of amlodipine besylate and olmesartan medoxomil with a variety of pharmaceutical excipients. Both drugs are antihypertensive agents that can be administered alone, in monotherapy, or in pharmaceutical association. The studies were performed
Ferrán Catalá-López et al.
PLoS medicine, 13(3), e1001971-e1001971 (2016-03-10)
Medications aimed at inhibiting the renin-angiotensin system (RAS) have been used extensively for preventing cardiovascular and renal complications in patients with diabetes, but data that compare their clinical effectiveness are limited. We aimed to compare the effects of classes of
Elham Bakhtiari et al.
Toxicology mechanisms and methods, 25(8), 614-621 (2015-09-04)
Over expression of renin-angiotensin system (RAS) and nuclear factor-kappaB (NF-κB) has a major role in many cancers. It has been suggested that some angiotensin receptor blockers (ARBs) could reduce the proliferation of cancer cells. The role of NF-κB pathway has
Nanako Muraya et al.
Oxidative medicine and cellular longevity, 2018, 7635274-7635274 (2018-07-04)
Oxidative stress induced by hyperuricemia is closely associated with the renin-angiotensin system, as well as the onset and progression of cardiovascular disease (CVD) and chronic kidney disease (CKD). It is therefore important to reduce oxidative stress to treat hyperuricemia. We
Mi-Yeon Yu et al.
PloS one, 13(8), e0202676-e0202676 (2018-08-28)
Albuminuria is a predictor of disease progression in patients with chronic kidney disease (CKD). However, the ability of proteinuria parameters measured at various time periods to predict renal outcomes is unclear. This observational cohort study included 165 non-diabetic hypertensive CKD
Ver todos los artículos relacionados

Questions

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico